ARPA-H awards UT Health San Antonio $38 million to lead VITAL-H, the first Phase 3 trial testing drugs to extend healthspan

UT Health San Antonio/VITAL-H

The Advanced Research Projects Agency for Health awarded UT Health San Antonio up to $38 million to conduct VITAL-H, a nationwide Phase 3 clinical trial testing three FDA-approved drugs—rapamycin, dapagliflozin, and semaglutide—to see if they can delay age-related health and functional decline in generally healthy adults ages 60–65. The trial will enroll 726 participants.

• $38 million federal contract from ARPA-H PROSPR program
• First Phase 3 trial of repurposed drugs for aging in healthy populations
• 726 participants, 3-year follow-up, four-arm randomized design
• South Texas and Hispanic communities prioritized for enrollment